Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

NCT03497806 is registered in ClinicalTrials.gov with Finch Research and Development LLC. as lead sponsor.

NCT NCT03497806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03497806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Lead sponsor
Finch Research and Development LLC.
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2018
Completion date
April 1, 2021
Enrollment
132 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

c. diff, c. difficile, cdi, clostridium difficile infection, fecal microbiota, fecal transplant, fmt, rcdi, recurrent c. diff, recurrent cdi, recurrent clostridium difficile infection